CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy

Haematologica

Volumn 91, Issue 11, 2006, Pages 1577-1578

  Rawstron, Andy C ^a   Laycock Brown, Giles ^a   Hale, Geoff ^b   Davies, Faith E ^c   Morgan, Gareth J ^c   Child, J Anthony ^d   Hillmen, Peter ^a   Owen, Roger G ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Alemtuzumab; CD52 expression; Myeloma

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; DRUG EFFICACY; HUMAN; IN VIVO STUDY; MYELOMA; PLASMA CELL; PROTEIN EXPRESSION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MULTIPLE MYELOMA;

EID: 33750949350     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Keating MJ, Flinn I, Jai V, Binet JL, Hillmen, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
2. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-9.
3. Gasparetto C, Horwitz ME, Gockerman JP, de Castro CM, Moore JO, Smith CA, et al. Campath-1H may have activity in the treatment of multiple myeloma. Blood 2004;104:4931.
4. Carlo-Stella C, Di Nicola M, Longoni P, Cleris L, Milanesi M, Lavazza C, et al. Primary plasma cells expressing CD52 are efficiently targeted in vivo by alemtuzumab. Blood 2004;104:3460.
5. Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003;102:1075-7.
6. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.
7. Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma 2005;5:278-81.
8. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction or outcome and can be used to optimize therapy. Blood 2001;98:29-35.
9. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-100.
10. Owen RG, Rawstron AC, Osterborg A, Lundin J, Svensson G, Hillmen P. Activity of alemtuzumab (MabCampath) in relapsed/refractory Waldenstrom's macroglobulinemia. Blood 2003;102 Suppl 1.